RASSF6 Antibody

What is RASSF6 and why is it significant in cancer research?

RASSF6 is a member of the tumor suppressor Ras-association domain family (RASSF) proteins that functions as a Ras effector protein. It plays a critical role in mediating apoptosis through both caspase-dependent and caspase-independent pathways . RASSF6 is frequently suppressed in multiple human cancers, including colorectal, bladder, pancreatic, and gastric carcinomas, with low expression associated with poor prognosis . It exerts tumor suppressive functions by:

• Inducing cell cycle arrest and apoptosis

• Blocking MDM2-mediated p53 degradation

• Enhancing the interaction between pRb and protein phosphatase

• Suppressing the epithelial-mesenchymal transition (EMT)

• Inhibiting metastasis and invasion

Research suggests RASSF6 acts as a tumor suppressor even in p53-negative backgrounds, making it a valuable target for understanding cancer mechanisms .

What applications are RASSF6 antibodies typically used for?

RASSF6 antibodies are validated for multiple research applications including:

• Western blotting (WB)

• Immunohistochemistry (IHC)

• Immunocytochemistry (ICC)

• Immunofluorescence (IF)

• Immunoprecipitation (IP)

• ELISA

Most commercial antibodies detect endogenous levels of total RASSF6 protein . Different antibodies may show application-specific performance variations, so validation for your specific experimental design is recommended.

What sample types have been validated with RASSF6 antibodies?

Based on available research data, RASSF6 antibodies have been successfully used with:

• Human cancer cell lines (HCT116, DLD1, K562, T24, 5637)

• Human tissue samples (particularly cancer tissues)

• Subcellular fractions (nuclear and cytoplasmic)

• Immunoprecipitated protein complexes

Most commercially available antibodies are reactive to human RASSF6, with predicted cross-reactivity to other species based on sequence homology .

How should I optimize Western blot conditions for RASSF6 detection?

For optimal Western blot detection of RASSF6:

• Sample preparation: Consider using buffer containing 3M urea to fully solubilize RASSF6, followed by dialysis, as standard lysis buffers may not completely extract RASSF6 .

• Loading amount: Use approximately 30μg of total protein lysate as demonstrated in validated protocols .

• Antibody dilution: Start with 1/500 dilution for most commercial antibodies, but optimize based on your specific antibody .

• Expected band size: Prepare to visualize a band at approximately 43kDa for RASSF6 .

• Controls: Include both positive controls (cell lines known to express RASSF6) and negative controls (RASSF6-knockdown samples if available).

For enhanced detection, consider subcellular fractionation, as RASSF6 can be found in both cytoplasmic and nuclear fractions with different patterns of phosphorylation .

What cell lines serve as appropriate positive and negative controls for RASSF6 studies?

Based on published research:

Positive controls (high RASSF6 expression):

• 5637 bladder cancer cell line

• Some colorectal cancer cell lines (validate expression first)

Cell lines for RASSF6 manipulation:

• HCT116 (used successfully for RASSF6 knockdown)

• DLD1 (used successfully for RASSF6 overexpression)

• T24 bladder cancer cells (used for RASSF6 overexpression)

When selecting control cell lines, consider that RASSF6 expression can vary significantly across cancer types and even within the same cancer type. Validation of RASSF6 expression in your chosen cell lines is recommended before proceeding with experiments .

How can I design experiments to investigate RASSF6's role in apoptosis pathways?

To study RASSF6's role in apoptosis:

• Create stable cell lines:

  • Establish RASSF6-overexpressing cells

  • Generate RASSF6 knockdown cells using siRNA or shRNA (RF-shRNA1 and RF-shRNA2 constructs have been validated)

• Apoptosis stimulation:

  • Treat cells with apoptosis inducers like doxorubicin (1μM has been validated)

  • Alternative inducers include tumor necrosis factor α, okadaic acid, or sorbitol

• Apoptosis assessment:

  • AnnexinV/PI staining followed by flow cytometry

  • Measure mitochondrial membrane potential using JC-1 staining

  • Western blot analysis of apoptotic markers (cytochrome c, cleaved caspase-3, cleaved caspase-9)

• Investigate pathway-specific effects:

  • Examine p53-dependent mechanisms by comparing results in p53-positive and p53-negative HCT116 cells

  • Analyze pRb-mediated mechanisms by examining pRb phosphorylation status

  • Study Hippo pathway involvement by assessing YAP expression/activity

This multi-faceted approach allows for comprehensive analysis of both caspase-dependent and caspase-independent apoptotic mechanisms regulated by RASSF6 .

How can I resolve issues with weak or non-specific RASSF6 signal in Western blots?

When facing detection challenges with RASSF6 antibodies:

• Solubilization issues:

  • RASSF6 may not fully solubilize in standard lysis buffers

  • Try lysis buffer containing 3M urea, followed by dialysis before immunoprecipitation or Western blotting

• For weak signals:

  • Increase antibody concentration (up to 1/250 dilution)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced chemiluminescence detection systems

  • Consider using Phos-tag gels to better separate phosphorylated and unphosphorylated forms

• For non-specific bands:

  • Increase blocking time and concentration

  • Perform additional washing steps

  • Use validated RASSF6 knockdown samples as negative controls

  • Consider using different antibody clones targeting distinct epitopes

• For subcellular localization studies:

  • Note that RASSF6 distributes differently between cytoplasm and nucleus

  • RASSF6 may relocalize when co-expressed with binding partners like pRb

What are the critical factors for successful immunoprecipitation of RASSF6 and its binding partners?

For effective RASSF6 immunoprecipitation:

• Lysis conditions:

  • Use buffer containing 3M urea for complete solubilization followed by dialysis

  • For protein interaction studies, gentler lysis conditions may be needed to preserve interactions

• Antibody selection:

  • Choose antibodies validated for IP applications

  • Consider using tag-based systems (FLAG-RASSF6, V5-pRb) for interaction studies as demonstrated in published research

• For Ras-RASSF6 interactions:

  • Controversy exists regarding direct binding - Allen et al. demonstrated RASSF6 binds Ki-Ras in a GTP-dependent manner requiring farnesylation

  • Others suggest interaction may be indirect or context-dependent

• For known interaction partners:

  • pRb: Successfully co-immunoprecipitated with RASSF6

  • E2F1: Interaction enhanced by RASSF6

  • Protein phosphatases: RASSF6 enhances PP1A and PP2A binding to pRb

• Controls:

  • Include IgG control

  • Use RASSF6-knockdown samples

  • Consider reverse IP (immunoprecipitate the binding partner and probe for RASSF6)

What considerations are important when using RASSF6 antibodies for immunohistochemistry?

For successful RASSF6 immunohistochemistry:

• Tissue preparation:

  • Formalin-fixed paraffin-embedded (FFPE) tissue sections have been successfully used

  • Optimal section thickness: 4-5μm

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) is typically required

  • Citrate buffer (pH 6.0) is commonly used

• Antibody selection:

  • Choose antibodies specifically validated for IHC applications

  • Start with recommended dilutions and optimize as needed

• Interpretation guidelines:

  • RASSF6 shows both cytoplasmic and nuclear staining patterns

  • Expression levels have been categorized in cancer studies as high or low based on staining intensity and percentage of positive cells

  • In colorectal cancer studies, decreased RASSF6 expression correlated with tumor size, lymph node status, and distant metastasis

• Controls:

  • Include normal adjacent tissue as internal control

  • Consider tissue microarrays (TMAs) to validate antibody performance across multiple samples simultaneously

How can I investigate the role of RASSF6 in the p53-independent tumor suppression mechanisms?

To study p53-independent functions of RASSF6:

• Experimental models:

  • Use p53-null cell lines (e.g., p53-negative HCT116 cells)

  • Compare effects of RASSF6 manipulation in p53-positive vs. p53-negative isogenic cell lines

• Key pathway analysis:

  • Examine pRb phosphorylation status at multiple sites (serine-608, threonine-821, serine-807/811)

  • Use Phos-tag gels to separate phosphorylated and unphosphorylated pRb

  • Analyze E2F1-pRb interaction through co-immunoprecipitation

  • Evaluate expression of E2F1 target genes

• Protein-protein interaction studies:

  • Investigate RASSF6-pRb interaction

  • Examine RASSF6's effect on protein phosphatase (PP1A, PP2A) recruitment to pRb

  • Analyze nuclear localization of RASSF6 in the presence of pRb

• Functional assays:

  • Measure polyploidy in p53-negative cells with RASSF6 depletion

  • Evaluate expression of TP73 target genes (p53 family member)

  • Assess P16INK4A and P14ARF expression in relation to BMI1 suppression

These approaches can help elucidate the mechanisms by which RASSF6 maintains tumor suppressive functions even when p53 is mutated or absent, a common scenario in many cancers .

What methodologies can be used to study RASSF6's role in epithelial-mesenchymal transition (EMT) and metastasis?

To investigate RASSF6's impact on EMT and metastasis:

• Gene expression analysis:

  • Examine changes in epithelial markers (ZO-1, E-cadherin) and mesenchymal markers (Snail) after RASSF6 manipulation

  • Use both qPCR and Western blotting to confirm changes at mRNA and protein levels

• In vitro metastasis assays:

  • Transwell migration assays

  • Matrigel invasion assays

  • Wound healing assays with RASSF6-overexpressing or RASSF6-knockdown cells

• Wnt signaling pathway assessment:

  • Analyze expression of Wnt target genes (c-Myc, c-Jun, TCF1)

  • Perform rescue experiments using Wnt activators (e.g., LiCl)

  • Evaluate β-catenin localization and activity

• In vivo metastasis models:

  • Hepatic and lung metastasis models have been established

  • Inject RASSF6-manipulated cells through the tail vein or spleen

  • Monitor metastatic burden through bioluminescence imaging or end-point analysis

• Clinical correlation:

  • Compare findings with patient data on RASSF6 expression and metastatic status

  • Research has shown RASSF6 downregulation is significantly associated with distant metastasis (p<0.001) in colorectal cancer patients

This comprehensive approach allows for mechanistic understanding of how RASSF6 regulates metastatic processes in cancer progression.

How can researchers investigate the relationship between RASSF6 and chemosensitivity in cancer cells?

To study RASSF6's role in chemosensitivity:

• Experimental design:

  • Generate RASSF6-overexpressing and RASSF6-knockdown cell lines

  • Treat cells with chemotherapeutic agents (doxorubicin has been validated at 1μM)

  • Measure cell viability using MTT assay or similar methods

  • Analyze apoptosis using Annexin V/PI staining

• Mitochondrial function assessment:

  • Measure mitochondrial membrane potential using JC-1 staining

  • Analyze cytochrome c release into the cytosol

  • Evaluate activation of the mitochondrial apoptotic pathway (cleaved caspase-9, cleaved caspase-3)

• Pathway analysis:

  • Investigate the Hippo signaling pathway, particularly YAP expression

  • Perform YAP knockdown experiments to determine if RASSF6's effects on chemosensitivity are YAP-dependent

  • Analyze Bcl-xL expression, which is regulated by YAP and affected by RASSF6

• Rescue experiments:

  • Use YAP siRNA to abolish the effects of RASSF6 on drug-induced apoptosis

  • Employ Hippo pathway modulators to determine pathway specificity

• Clinical correlation:

  • Compare RASSF6 expression levels in patient samples with response to chemotherapy

  • Analyze publicly available datasets for correlations between RASSF6 expression and treatment outcomes

Research has shown that RASSF6 overexpression increases sensitivity to doxorubicin by affecting mitochondrial membrane potential and enhancing apoptosis, potentially through the Hippo signaling pathway by downregulating YAP .

How can RASSF6 research inform cancer biomarker development and therapeutic strategies?

RASSF6 research has several translational implications:

Future research integrating RASSF6 status with other molecular markers may lead to improved personalized treatment approaches for cancer patients.

What are the challenges and considerations in studying RASSF6 interactions with the Hippo tumor suppressor pathway?

Investigating RASSF6-Hippo pathway interactions presents several challenges:

• Complexity of interactions:

  • RASSF6 interacts with MST1/MST2 kinases and inhibits their kinase activity

  • Reciprocally, MST1/MST2 suppress RASSF6-induced apoptosis

  • Pathway activation causes dissociation of RASSF6 and MST1/MST2

• Context-dependent effects:

  • RASSF6 functions may vary across different cell types and cancer contexts

  • Interactions may depend on specific stimuli (e.g., okadaic acid exposure)

• Methodological considerations:

  • Need for appropriate controls when manipulating both RASSF6 and Hippo pathway components

  • Potential confounding from compensatory mechanisms within the Hippo network

  • Requirement for both gain- and loss-of-function approaches

• Investigation strategies:

  • Use LATS1/LATS2 knockdown to assess RASSF6 function independent of these Hippo pathway components

  • Analyze LIN52 (DREAM complex component) to differentiate RASSF6 effects from DREAM-mediated regulation

  • Examine YAP phosphorylation and nuclear localization in response to RASSF6 manipulation

• Validation approaches:

  • Compare findings across multiple cell lines with different baseline Hippo pathway activities

  • Use rescue experiments with constitutively active or dominant-negative Hippo pathway components

  • Employ in vivo models to validate cell culture findings

Research indicates that while RASSF6 affects YAP through the Hippo pathway, it can also function independently of core Hippo components like LATS1/LATS2, suggesting complex regulatory relationships .

How should researchers approach contradictory findings in the literature regarding RASSF6's interaction with Ras proteins?

When addressing conflicting findings on RASSF6-Ras interactions:

• Technical factors to consider:

  • Protein solubilization methods significantly impact detection of interactions

  • Using buffer containing 3M urea (followed by dialysis) may yield different results than standard approaches

  • Immunoprecipitation conditions and stringency affect observed interactions

• Experimental validation approaches:

  • Compare direct binding using purified recombinant proteins

  • Evaluate GTP-dependency of interactions with active and inactive Ras mutants

  • Assess requirement for post-translational modifications like farnesylation

• Specific contradictions to address:

  • Allen et al. demonstrated RASSF6 binding to Ki-Ras in a GTP-dependent manner requiring farnesylation

  • Other studies failed to detect direct RASSF6-Ras binding under certain conditions

  • Some evidence suggests possible indirect interactions or context-dependent binding

• Resolution strategies:

  • Perform comparative studies using different RASSF family members as controls (e.g., Nore1/RASSF5 shows consistent Ras binding)

  • Investigate potential bridging proteins that might mediate indirect interactions

  • Examine functional consequences of disrupting putative Ras-RASSF6 interactions

• Functional validation:

  • Determine whether Ras-mediated effects require RASSF6

  • Evaluate whether RASSF6's tumor suppressor functions depend on Ras binding